Theme 1: Advances in Process Control, Modeling, and Analytics
Recent advances in data analytics and process analytical technologies (PAT) have enabled real-time monitoring and control of parameters, improving quality and robustness for both batch and continuous processes. This theme will cover the current state of process control, modeling, and analytics for the manufacture of biologic and chemical entities. The focus will be on process control, encompassing data analytics, process modeling, machine learning, implementation of PAT and real time release testing (RTRT). Examples could include development and use of data lakes, advanced statistics and process modeling approaches, performance monitoring, and deployment of automated feedback / feedforward control.
Theme 2: Manufacturing and Analytical Challenges of Emerging Therapeutic Modalities and Novel Delivery Systems
With recent approvals for several new therapeutic modalities including chimeric antigen receptor T cells (CAR-T), gene therapy, and oligonucleotide products, manufacturing science is extending beyond the current small and large molecule platforms. This theme will cover the nascent science, analytical characterization and regulatory aspects of manufacturing emerging therapeutic products, devices, drug device combinations, and drug delivery systems. Some examples could include recent advances in cell therapy manufacturing, viral vector / gene therapy manufacturing, in-process control and validation of new modality processes, and facility design considerations. Analytical characterization of cell and gene therapy products, oligonucleotides, and other unique formulations such as aerosols, topicals, liposomes, amorphous materials and customized release products could be covered.
Theme 3: Next Generation Manufacturing Enabling Speed to Patient
For patients facing serious disease, speed is critical. This theme will cover next-generation development and manufacturing approaches for traditional therapeutic products, enabling speed to patient. Topics could include process intensification, speed through deployment of continuous and single-use manufacturing technologies, 3D printed pharmaceuticals, and elimination of scale-up and tech transfer. Strategies such as registration-ready clinical campaigns, breakthrough therapy designations, analytical roadmaps, identification / justification of Critical Quality Attributes (CQAs), and stability approaches could be discussed. Health agency guidance and sponsor experience, presented as case studies, will be considered for this session.
Register for PharmSci 360 today!
Introducing Connect 360
Connect 360 is an AI-driven, matchmaking tool that helps you find new contacts based on your shared interests. You can message other attendees and meet with them by video chat. You can also block your calendar so that other registrants know when you're available.
Last Chance to Submit an Abstract for October’s PharmSci 360
Encouraging Authors and Registrants to Connect Is AAPS’ Priority
Submission Deadline August 12 at 5pm ET
PharmSci 360 will bring scientists from around the world together Oct. 26 – Nov. 5, including poster authors.
AAPS has made conversations between authors and registrants a top priority for the poster program this year.
“PharmSci 360 brings together thousands of scientists from across the pharmaceutical discovery and development spectrum,” Executive Director Tina Morris, Ph.D., said. “Authors come to AAPS in hopes of connecting with scientists from various disciplines who can give them feedback that helps them advance their work. We’re building pathways to ensure those conversations happen this year. They’re a critical part of a successful meeting for us.”
Authors can expect:
- To add an audio narration to accompany their poster
- To be able to contact any registrant through Connect 360—PharmSci 360’s networking platform—throughout the two-week event to invite them to discuss a poster
- To have their posters found through a database system that lets registrants search by keywords and find posters -- an important feature to the editors, hiring managers, and potential collaborators who scour PharmSci 360 each year for authors they want to get to know better
The posters of Best Abstract Winners, which are determined by the Abstract Screening Committee, will be recognized with banners on the posters themselves that registrants can see when they view the online poster catalog.
AAPS is also laying plans for Special Poster Collection presentations, in which authors will meet with leaders and members who have selected their abstracts for additional discussion.
AAPS’ Board of Directors recognize that many researchers have been unable to access their offices and labs, and so they’ve waived one of association’s long-standing requirements: This year, AAPS will accept abstracts that do not include data. Authors are expected to provide data with the poster when it is submitted in October.
The Late Breaking Abstract (LBA) deadline is August 12 at 5 pm ET. Read the addendum to the 2020 Call for Poster Abstracts to learn what AAPS requires in abstracts this year, and then submit your abstract!
2020 AAPS PharmSci 360 – Call for Volunteer Abstract Screeners
Deadline to complete online sign-up is August 12 at 5pm ET
AAPS seeks volunteer poster abstract screeners to review late breaking abstracts for the 2020 PharmSci 360.
To be a screener you must agree to:
- Review and select the Review Groups in which you are experienced. The Review Groups correspond to PharmSci 360’s tracks and topics.
- Review Screener Training before screening begins.
- Spend a few minutes familiarizing yourself with the applicable literature in your area of expertise.
- Spend a few minutes reading each abstract assigned to you and answering a few questions about it.
- Review assigned abstracts August 14—August 31, 2020.
Ready to apply?